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Methicillin-resistant Staphylococcus aureus (MRSA) infections have grown to epidemic proportions 
in the United States. With the development of increasing drug resistance of MRSA to traditional 
antimicrobials, there has been a search for a more effective antibiotic treatment. Linezolid is one of 
the most effective oral medications used for outpatient treatment of MRSA infections. We present a 
case of pancytopenia after outpatient treatment with linezolid. Myelosuppression is a rare but serious 
side effect of linezolid of which emergency physicians need to be aware in order to provide early 
intervention. 
[WestJEM. 2008;9:177-178.]
INTRODUCTION
Since their emergence onto the clinical scene in the 1960s, 
methicillin-resistant strains of Staphylococcus aureus (MRSA) 
have continued to plague clinicians. MRSA is no longer 
solely a nosocomial infection and has now become the most 
common cause of skin and soft tissue infections presenting 
in emergency departments (EDs).1,2 With the expanding 
resistance to multiple antibiotics, physicians are faced with the 
challenge of finding effective outpatient therapy. Linezolid is 
effective against multiple strains of MRSA and is available in 
an oral formulation for outpatient therapy.1 We present a case 
of linezolid-induced myelosuppression. Myelosuppression is a 
rare yet significant side effect reported during post-marketing 
use of linezolid. ED physicians need to be aware of this 
serious side effect, which may place the patient at risk for 
further health-related complications as a result of cytopenias.
 
CASE REPORT
A 73-year-old female presents to the ED complaining of 
generalized weakness. The patient reported weight loss due 
to nausea, vomiting, and decreased appetite for two months. 
The patient had no known drug allergies and denied tobacco, 
alcohol, or illicit drug use. Review of systems included 
dyspnea on exertion and fatigability. Past medical history 
included a lumbar fracture due to a motor vehicle accident, 
requiring lumbar fusion. The patient later developed recurrent 
osteomyelitis of the lumbar vertebrae. Repeated incision and 
drainage of the abscesses at her previous surgical site showed 
persistent MRSA-positive wound cultures. Subsequently, 
inpatient treatment with intravenous vancomycin for MRSA 
osteomyelitis of the lumbar spine was instituted. The patient 
had been discharged on oral linezolid for continued outpatient 
treatment for MRSA at a dose of 600 mg twice a day for six 
weeks, with Zofran as needed for nausea and vomiting.
On this visit, the patient was in no acute distress and 
nontoxic appearing. Her mucus membranes were pale, with 
no gingival bleeding; the funduscopic eye exam was normal. 
The lungs were bilaterally clear to auscultation; the heart had 
a regular rate and rhythm with no murmurs, gallops or rubs. 
Abdominal exam was soft, non-tender, non-distended with 
normoactive bowel sounds. A rectal exam revealed normal 
tone, brown stool was hemoccult negative. Extremities 
exhibited full range of motion and intact neurovascularization; 
the skin was without rashes and petechiae; pulses were 
full throughout. Exam of the back demonstrated a healed 
incision in the lumbar region, correlating with the previous 
surgeries; no erythema, tenderness, warmth, rashes, lesions, 
open wounds, or fluctuance were noted. Cranial nerves II-XII 
were intact; motor and sensory exams, reflexes, and gait were 
normal with no focal neurologic signs. 
ED laboratory tests included a complete metabolic panel, 
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enzymes, partial thromboplastin time, prothrombin time and 
INR, and reticulocyte count. All labs were within normal 
limits, except the CBC, which reported a white blood cell 
count of 2,100 with a normal differential, hemoglobin of 4.2, 
platelet count of 64,000, with normal red blood cell indices 
and normal peripheral smear. EKG and chest x-ray were 
normal. Inpatient TIBC, iron and transferrin levels, and high 
reticulocyte values were consistent with iron deficiency and 
active bone marrow response.
The patient was admitted for treatment of linezolid-
induced myelosuppression. She received IV fluids and was 
transfused with packed red blood cells due to symptomatic 
anemia. Treatment with linezolid was discontinued, and the 
patient was restarted on IV-administered vancomycin. Her 
hospitalization was uneventful, and the patient’s cell counts 
returned to baseline, without the need for a bone marrow 
biopsy. A peripherally inserted central catheter line was placed 
and the patient was discharged home to continue outpatient 
IV therapy with vancomycin for her persistent MRSA 
osteomyelitis. 
 DISCUSSION
MRSA infections present most commonly as skin or 
soft tissue infections, in the form of cellulitis, furuncles or 
abscess, as well as more serious infections, such as pneumonia 
and sepsis. MRSA infections have historically occurred 
more frequently in hospitalized patients with compromised 
immune systems. More recently, community-acquired MRSA 
infections are of epidemic proportions in previously low-risk 
groups in the United States.3,4 The genetic element that confers 
methicillin resistance continues to evolve, creating multi-drug 
resistant strains. Without a definitive marker for identifying 
MRSA strains, outpatient treatment continues to challenge the 
medical community.1,5
Historically, MRSA has been treated successfully 
with outpatient oral sulfonamides, clindamycin, rifampin, 
doxycycline, or a combination of these agents.5 With the 
development of increasing drug resistance of MRSA to these 
traditional antimicrobials, there has been a search for more 
effective antibiotics. One recent study demonstrated that 
vancomycin, linezolid, and quinupristin-dalfopristin were the 
most effective antibiotics against multiple strains of MRSA.1 
The parenteral administration of vancomycin and quinupristin-
dalfopristin has limited their use in the outpatient setting; 
however, the availability of an oral formulation of linezolid 
has lead to its increasing utilization.
Linezolid is an oxazolidinone antibiotic indicated for the 
treatment of Gram-positive bacterial infections, including 
bacterial pneumonia, skin and soft tissue infections, and 
vancomycin-resistant enterococcal infections. The most 
common adverse effects include diarrhea, nausea, and 
headache; less common side effects include hypertension, 
lactic acidosis, and elevated liver enzymes. Among the most 
severe adverse effects, seen with prolonged courses of therapy, 
include irreversible peripheral neuropathy, optic neuropathy, 
and reversible myelosuppression.8
Oral linezolid is now being prescribed more frequently 
for outpatient treatment of MRSA due to the increase in 
multi-drug resistant microbes. In the literature, five cases of 
linezolid-induced myelosuppression have been reported.6,7 
Of these cases, four reported anemia and thrombocytopenia 
and only one case reported pancytopenia. In this case, 
pancytopenia developed after only six weeks of therapy, 
whereas the other case reported pancytopenia developing 
after five months of treatment with linezolid. In addition 
to our patient, three of the five reported cases had their 
myelosuppression reversed after discontinuation of linezolid.7 
Per the manufacturer’s recommendation, patients on linezolid 
therapy for longer than two weeks should be monitored 
regularly in order to identify myelosuppression. 
Emergency physicians need to be aware of this rare and 
serious side effect of linezolid-induced myelosuppression. 
Address for Correspondence: Julie Gorchynski, MD,MSc, 
Department of Emergency Medicine, Texas A&M University 
System, CHRISTUS Spohn Memorial Hospital, 2606 Hospital 
Blvd. 3W, Corpus Christi, TX 78405. Email: jgorchyn@msn.com.
REFERENCES
Draghi DC, Sheehan DF, Hogan P, Sahm DF. Current antimicrobial  1. 
resistance profiles among methicillin-resistant Staphylococcus 
aureus encountered in the outpatient setting. Diagn Microbiol Infect 
Dis. 2006; 55:129-133.
Ahmad K. MRSA becomes growing problem in US emergency  2. 
departments. Lancet Infect Dis. 2006; 6:621.
National Library of Medicine: MedlinePlus. (2007 May 02).  3.  MRSA 
infection. Available at: http://www.nlm.nih.gov/medlineplus/ency/
article/007261.htm. Accessed May 8, 2007.
Centers for Disease Control and Prevention.  4.  Community-
Associated MRSA Information for Clinicians. 2005; Available at: 
http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_clinicians.html. 
Accessed May 8, 2007.
Elston DM. Methicillin-Sensitive and Methicillin-Resistant  5. 
Staphylococcus aureus: Management Principles and Selection of 
Antibiotic Therapy. Dermatol Clin. 2007; 25:157-164.
Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated  6. 
cytopenias, but not peripheral neuropathy, by administration of 
vitamin B6. J Antimicrob Chemother. 2004; 54:832-835.
Green SL, Maddox JC, Huttenbach ED. Linezolid and Reversible  7. 
Myelosuppression. JAMA. 2001; 285:1291.
Pfizer, Inc. Zyvox prescribing information. 2007; Available at: www. 8. 
zyvox.com/prescribingInfo.asp. Accessed May 23, 2007.
Linezolid-induced Pancytopenia  Gorchynski et al